Hangzhou AGS MedTech Co. Ltd. A (688581) — Capital Reinvestment Ratio
Hangzhou AGS MedTech Co. Ltd. A (688581) has a Capital Reinvestment Ratio of 0.42x as of December 2025, meaning it reinvests 0% of its operating cash flow (CN¥151.20 Million) in capital expenditures (CN¥63.47 Million). Check 688581 tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Hangzhou AGS MedTech Co. Ltd. A Capital Reinvestment Ratio (2021–2025)
This chart tracks Hangzhou AGS MedTech Co. Ltd. A's Capital Reinvestment Ratio across 5 annual periods. For the full cash flow conversion analysis, see Hangzhou AGS MedTech Co. Ltd. A operating cash flow efficiency.
Annual Capital Reinvestment Ratio for Hangzhou AGS MedTech Co. Ltd. A (2021–2025)
Year-by-year Capital Reinvestment Ratio for Hangzhou AGS MedTech Co. Ltd. A from 2021 to 2025. See cash generation quality of Hangzhou AGS MedTech Co. Ltd. A to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.42x | CN¥151.20 Million | CN¥63.47 Million | ▲ +167.2% |
| 2024 | 0.16x | CN¥315.80 Million | CN¥49.60 Million | ▼ -32.6% |
| 2023 | 0.23x | CN¥221.45 Million | CN¥51.57 Million | ▼ -39.4% |
| 2022 | 0.38x | CN¥156.38 Million | CN¥60.12 Million | ▲ +190.3% |
| 2021 | 0.13x | CN¥118.25 Million | CN¥15.66 Million | — |